NASDAQ:KOOL Cesca Therapeutics (KOOL) Stock Price, News & Analysis → 4x Better than Bitcoin (From Behind the Markets) (Ad) Free KOOL Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$2.11▼$5.1452-Week Range N/AVolume15,122 shsAverage Volume112,188 shsMarket Capitalization$1.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Cesca Therapeutics alerts: Email Address Ad Behind the Markets4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Cesca Therapeutics Stock (NASDAQ:KOOL)Cesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. It offers AutoXpress System, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood; Point-of-CareXpress System, a proprietary automated device and companion sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow; CAR-TXpress System, a suite of multi-component automated system that allows the automated manufacturing, expansion, and storage of cellular therapies for immuno-oncology; BioArchive System, an automated cryogenic device for single-cassette based cryo-storage of biological license applications products; and manual bag sets for use in the processing and cryogenic storage of cord blood. The company is also developing autologous stem cell-based therapies that address medical needs for applications in the vascular, cardiology, and orthopedic markets. In addition, it provides cell manufacturing and banking services. The company was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California. Cesca Therapeutics Inc. is a subsidiary of Boyalife (Hong Kong) Limited.Read More Ad Behind the Markets4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> KOOL Stock News HeadlinesAugust 12, 2023 | nj.comNew book by Kool & the Gang member; Junior Police Academy a success | Journal EntriesJune 5, 2023 | msn.comSolo artist Cesca ‘happy’ to team up with BGYO’s MikkiMarch 29, 2024 | Behind the Markets (Ad)4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 25, 2023 | msn.com'Maybe Next Time' adaptation: All we know about Apple Studios and Cesca Major movieApril 29, 2022 | yahoo.comCesca Chairs Are Our Latest (But Oldest) Design ObsessionMarch 21, 2022 | msn.comCesca’s ‘Pambihirang Harana’ song aims to normalize girls initiating relationshipsSee More Headlines Receive KOOL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cesca Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2018Today3/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Laboratory Apparatus & Furniture Sub-IndustryN/A Current SymbolNASDAQ:KOOL CUSIPN/A CIK811212 Webwww.cescatherapeutics.com Phone916-858-5100FaxN/AEmployees53Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,720,000.00 Net Margins-98.84% Pretax MarginN/A Return on Equity-77.30% Return on Assets-37.75% Debt Debt-to-Equity Ratio0.50 Current Ratio1.52 Quick Ratio0.91 Sales & Book Value Annual Sales$9.67 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$3.11 per share Price / BookN/AMiscellaneous Outstanding Shares2,416,000Free FloatN/AMarket Cap$1.83 million OptionableNot Optionable Beta1.07 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Xiaochun Xu M.B.A. (Age 48)Ph.D., Chairman, CEO & Pres Mr. Jeff Cauble (Age 46)Principal Financial & Accounting Officer Mr. James Xu J.D. (Age 48)L.L.M., M.B.A., Director, Gen. Counsel, Sr. VP of Legal Affairs & Cybersecurity and Corp. Sec. Mr. Philip H. Coelho (Age 75)Chief Technology Officer Ms. Haihong ZhuPres of ThermoGenesisKey CompetitorsThermoGenesisNASDAQ:THMOWindtree TherapeuticsNASDAQ:WINTNeuBase TherapeuticsNASDAQ:NBSEPhio PharmaceuticalsNASDAQ:PHIONanoVibronixNASDAQ:NAOVView All Competitors KOOL Stock Analysis - Frequently Asked Questions How were Cesca Therapeutics' earnings last quarter? Cesca Therapeutics Inc (NASDAQ:KOOL) posted its quarterly earnings results on Monday, May, 14th. The biotechnology company reported ($0.27) EPS for the quarter. The biotechnology company earned $1.87 million during the quarter. Cesca Therapeutics had a negative net margin of 98.84% and a negative trailing twelve-month return on equity of 77.30%. What other stocks do shareholders of Cesca Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cesca Therapeutics investors own include CTI BioPharma (CTIC), SCYNEXIS (SCYX), NVIDIA (NVDA), QUALCOMM (QCOM), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Advanced Micro Devices (AMD). This page (NASDAQ:KOOL) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cesca Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.